1,955 Shares in AtriCure, Inc. (NASDAQ:ATRC) Purchased by Heck Capital Advisors LLC

Heck Capital Advisors LLC bought a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,955 shares of the medical device company’s stock, valued at approximately $60,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Sei Investments Co. raised its stake in shares of AtriCure by 68.2% during the second quarter. Sei Investments Co. now owns 38,316 shares of the medical device company’s stock valued at $872,000 after purchasing an additional 15,534 shares in the last quarter. Bank of Montreal Can increased its stake in AtriCure by 4.0% during the 2nd quarter. Bank of Montreal Can now owns 21,441 shares of the medical device company’s stock valued at $488,000 after buying an additional 831 shares during the period. AQR Capital Management LLC raised its position in shares of AtriCure by 38.2% during the 2nd quarter. AQR Capital Management LLC now owns 58,738 shares of the medical device company’s stock worth $1,337,000 after buying an additional 16,251 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of AtriCure by 6.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,919 shares of the medical device company’s stock worth $567,000 after acquiring an additional 1,429 shares during the period. Finally, Truist Financial Corp boosted its holdings in shares of AtriCure by 13.8% in the second quarter. Truist Financial Corp now owns 15,184 shares of the medical device company’s stock valued at $346,000 after acquiring an additional 1,842 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Performance

Shares of ATRC stock opened at $39.87 on Monday. The stock’s fifty day simple moving average is $34.72 and its 200-day simple moving average is $30.25. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -48.04 and a beta of 1.42. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.11.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ATRC shares. Canaccord Genuity Group upped their target price on AtriCure from $53.00 to $61.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Needham & Company LLC raised their target price on AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. UBS Group lifted their target price on AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $40.00 price target on shares of AtriCure in a report on Tuesday, December 17th. Finally, Oppenheimer lifted their price objective on shares of AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.38.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.